Clinical trials: Prostate Cancer, Castration Resistant
Prostate Cancer
Phase I Trial of 225Ac-J591 in Patients With mCRPC
This is an open-label, single-center Phase I dose escalation study designed to determine the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of 225Ac-J591 in a single dose regimen.
- Trial name
- NCT03276572
- Testing
- 225Ac-J591
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Weill Medical College of Cornell University
mCRPC (Metastatic Castration-resistant Prostate Cancer), Advanced Malignant Solid Tumor
A Study of MHB048C in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I/II study of MHB048C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT07192120
- Testing
- MHB048C for Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
This phase II trial tests whether cabozantinib and atezolizumab work to shrink tumors in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- AtezoCab (NCT05168618)
- Testing
- Atezolizumab, Cabozantinib S-malate
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Utah
Solid Tumors, Advanced Triple Negative Breast Cancer
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
This is a Phase 1b/2a dose escalation and expansion, multi-center study to be conducted in 2 phases: Phase 1b Dose Escalation Part 1 (Doublet Therapy) Dose Escalation Part 2 (Triplet Therapy) Phase 2a Dose Expansion (Triplet…
- Conditions
- Solid Tumors, Advanced Triple Negative Breast Cancer, Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer, Advanced Metastatic Castration-Resistant Prostate Cancer
- Trial name
- NCT03861403
- Testing
- TRX518, Cyclophosphamide, Avelumab
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Leap Therapeutics, Inc.
Prostate Cancer
Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to find out what effects a new drug, palbociclib, has on prostate cancer and will look at the side effects of treatment with palbociclib.
- Trial name
- NCT02905318
- Testing
- Palbociclib
- Where
- 7 sites in Canada
- Volunteers
- 19 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer
Ipilimumab, an antibody that blocks cytotoxic T-lymphocyte antigen 4, and GVAX have demonstrated anti-tumor activity in prostate cancer. Pre-clinical studies with this combination have demonstrated potent synergy.
- Trial name
- NCT01510288
- Testing
- GVAX and ipilimumab
- Where
- Netherlands
- Volunteers
- 28 people
- Sponsor
- Amsterdam UMC, location VUmc
Prostate Cancer
ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug combination of ARRx (also known as AZD5312) plus enzalutamide in patients with metastatic…
- Trial name
- NCT03300505
- Testing
- ARRx, Enzalutamide
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of Michigan Rogel Cancer Center
Metastatic Castration-resistant Prostate Cancer (CRPC), Metastatic Castration-resistant Prostate Carcinoma
Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer
TITLE: Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9bMS in Patients with Prostate Cancer (PHAROS) STUDY DESCRIPTION: Prostate cancer (PC) patients receive androgen deprivation…
- Trial name
- PHAROS (NCT06705686)
- Testing
- (R)-9bMS
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- TechnoGenesys, Inc.
Prostate Cancer
A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer
The purpose of this study is to assess the safety and efficacy in Korea or Taiwan of oral abiraterone acetate and oral prednisolone in men with metastatic-castration resistant prostate cancer (mCRPC) and with disease progression…
- Trial name
- NCT01685983
- Testing
- Abiraterone acetate, Prednisolone
- Where
- 8 sites in South Korea, Taiwan
- Volunteers
- 82 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer, Castration-resistant Prostate Cancer
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
This is a study to evaluate the safety and clinical activity of the combination of olaparib and high-dose IV ascorbate, as second or later line of therapy, in castration resistant prostate cancer patients with no known DNA repair…
- Trial name
- NCT05501548
- Testing
- Olaparib, Vitamin C
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
PSMA PET-Positive Castration-Resistant Prostate Cancer
Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer
Evaluating the safety and antitumor efficacy of 177Lu-LNC1011
- Trial name
- NCT06809426
- Testing
- 177Lu-LNC1011
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Affiliated Hospital of Jiangnan University
Prostate Cancer
Lenalidomide and Paclitaxel in Prostate Cancer
The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of Revlimid® (lenalidomide) that can be given in combination with paclitaxel to patients with prostate cancer who have failed…
- Trial name
- NCT00933426
- Testing
- Lenalidomide, Paclitaxel
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
This is a phase II multi-center study to determine the clinical impact of using a patient-specific genomic expression signature of androgen receptor (AR) activity to determine therapy for patients with castration-resistant…
- Trial name
- ARS (NCT00918385)
- Testing
- Nilutamide, Dasatinib
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Duke University
Prostate Cancer
Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)
This is an exploratory Phase 2 multicenter, randomized, open-label study with a randomization allocation ratio of 1:1 [abiraterone acetate + prednisone + LHRH-therapy (Arm A) versus abiraterone acetate + prednisone (Arm B)].
- Trial name
- SPARE (NCT02077634)
- Testing
- abiraterone acetate + prednisone + LHRH-therapy, abiraterone acetate + prednisone
- Where
- 22 sites in Germany
- Volunteers
- 68 people
- Sponsor
- Universität des Saarlandes
Prostate Cancer
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone.
- Trial name
- NCT03574571
- Testing
- Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223
- Where
- 72 sites in United States, Brazil and 2 more
- Volunteers
- 732 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Castration Resistant Prostate Cancer
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
The purpose of the study was to understand if there is benefit in treatment with a medicine called enzalutamide in the re-treatment setting.
- Trial name
- NCT02441517
- Testing
- Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Non-metastatic Castration-resistant Prostate Cancer
An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment
In this observational study, participants receive darolutamide: a treatment that is already available for doctors to prescribe for non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive…
- Trial name
- DARE (NCT07538843)
- Testing
- Darolutamide, ADT
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Bayer
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well orteronel works in treating patients with metastatic hormone-resistant prostate cancer. Orteronel may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01866423
- Testing
- orteronel, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Southern California
Prostate Cancer
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A 2-part, Phase 1-2, open-label, parallel group, randomized study in patients with Castration-Resistant Prostate Cancer (CRPC) who are no longer responding to treatment with abiraterone and steroids.
- Trial name
- NCT01685268
- Testing
- AT13387, abiraterone acetate, Prednisone
- Where
- 32 sites in United States, Canada and 2 more
- Volunteers
- 49 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
COMbination of Bipolar Androgen Therapy and Nivolumab
Single arm, multicenter, open-label Phase II study of the effects of parenteral testosterone in combination with nivolumab in men with metastatic castration-resistant prostate cancer who previously progressed on at least one…
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
- Trial name
- COMBAT-CRPC (NCT03554317)
- Testing
- Testosterone cypionate, Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.